Jaguar Health, Inc. current report, 24 August 2022

Full document

Jaguar Health, Inc. (JAGX) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated August 24, 2022, details a material definitive agreement entered into by Jaguar Health, Inc. The Company is a biopharmaceutical firm focused on the development and commercialization of Mytesi (crofelemer). The report covers the execution of a new royalty financing arrangement intended to fund ongoing clinical trials.

Key Financial Metrics and Transaction Details

  • Transaction Type: Royalty Interest Purchase Agreement.
  • Counterparty: Streeterville Capital, LLC (affiliated with Chicago Venture Partners, L.P.).
  • Proceeds Received: $4,000,000.
  • Repayment Obligation: $12,000,000 (Royalty Repayment Amount).
  • Interest Rate: 5% per annum for the first year; 10% per annum thereafter (simple interest).
  • Minimum Monthly Payments: Commencing January 1, 2024, starting at $250,000 and escalating to $750,000 by month 18.
  • Revenue Share: Investor receives 10% of net sales of crofelemer for specific indications, 10% of upfront licensing fees/milestones, and 50% of royalties from third-party licenses.
  • Use of Proceeds: Funding the pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adults receiving targeted cancer therapy.

Material Changes and Prior Agreements

This financing follows a series of prior royalty agreements totaling $17 million:

  • $6 million with Iliad Research and Trading, L.P. (Oct 2020, amended April 2022).
  • $6 million with Uptown Capital, LLC (Dec 2020, amended April 2022).
  • $5 million with Streeterville Capital, LLC (March 2021, amended April 2022).

The new agreement increases the Company's total royalty obligations and introduces a mechanism allowing the Company to exchange the royalty interest for Common Stock at the Nasdaq Minimum Price at its sole discretion.

Outlook, Risks, and Covenants

Management Commentary: The financing is designed to support critical clinical development without immediate dilution, though it creates significant future cash flow obligations tied to product sales.

Risks and Contingencies:

  • Liquidated Damages: Failure to comply with covenants (e.g., maintaining exchange listing, timely filings) may result in a 15% increase to the Royalty Repayment Amount.
  • Restrictions: The Company cannot sell substantially all assets or grant new security/royalty interests for capital raising without Investor consent.
  • Reporting: Quarterly revenue and net sales information must be provided to the Investor.

Unregistered Sales: The transaction was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.

Investor Verification Checklist

  • Verify the specific definitions of "Included Products" and "cannibalize crofelemer indications" to understand the scope of the 10% royalty.
  • Review the Company's current cash position against the escalating minimum monthly payment schedule starting January 2024.
  • Assess the progress and timeline of the Phase 3 clinical trial for targeted cancer therapy to gauge the likelihood of future royalty triggers.
  • Examine the total outstanding royalty obligations from prior agreements (Iliad, Uptown, and previous Streeterville deals) to calculate total future cash flow requirements.
  • Confirm the current Nasdaq Minimum Price to evaluate the potential dilution impact if the Company exercises its option to convert the royalty to equity.